Poolbeg Pharma PLC POLB

Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion about the company's interim results for the first half of 2026, progress with POLB 001 and the milestones investors can expect as its clinical development programme advances. Skillington said Poolbeg Pharma made "incredible progress" during the period, successfully transitioning POLB 001 from trial preparation into active clinical development. The programme is being studied in relapsed or refractory multiple myeloma patients, aiming to prevent cytokine release syndrome associated with cancer therapy. Th

Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion after a positive interim safety review of its TOPICAL clinical trial targeting cytokine release syndrome (CRS) linked to cancer therapies. The review recommended the trial continue unchanged, with recruitment ongoing at leading UK sites and further sites being activated. Skillington said the latest data adds to the preclinical evidence, previous trial data and intellectual property supporting POLB 001, while Poolbeg continues discussions with potential pharmaceutical partners. He said the focus now is o

Galliford Try (LSE:GFRD) has secured places across all five regional lots of a £9.5 billion public sector construction framework covering schools, colleges, universities and healthcare buildings across Great Britain. The framework can run for up to eight years. Poolbeg Pharma (AIM:POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cytokine release syndrome patent, following earlier grants in Europe, Australia and Canada. The growing patent estate is expected to strengthen the drug's appeal to potential commercial partners. Tertiary Minerals (AIM:TYM) has r

ACG Metals Ltd (LSE:ACG, OTC:ACGAF) beat its full-year oxide production target in just six months, helped by a 64% jump in its realised gold price to $4,838 an ounce. First copper and zinc concentrate production is now expected in August. Rockfire Resources (LSE:ROCK) has returned more strong zinc and silver grades at its Molaoi project in Greece, with preliminary readings showing zinc values as high as 37.7%. The company is fast-tracking feasibility studies and applying for permits to reopen the underground workings. Sunda Energy (AIM:SNDA) has applied for a permit to explore an offshore area

Poolbeg Pharma (AIM:POLB) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the dosing of the first patient in its Phase II study evaluating POLB-001 for the prevention of cytokine release syndrome in multiple myeloma patients receiving Johnson & Johnson's teclistamab. The trial is running across six UK sites, with the first patient dosed at The Christie Hospital in Manchester and University College London Hospitals now activated as the second recruiting centre. Poolbeg expects to enrol up to 30 patients and remains on track to deliver interim clinical data by the end of sum

Metals One (AIM:MET1) is consolidating its South African gold strategy, with a deal that would lift its stake in Lions Bay Capital to 54.3%. The transaction implies a 237% unrealised gain on its investments so far. EnergyPathways (AIM:EPP) says the next twelve months are critical for its MESH energy storage project, with a value prize running into the billions. The company's targeting a final investment decision and commercial operation by 2031. Zephyr Energy (AIM:ZPHR) is pushing its Paradox Basin project towards first commercial production after strong drilling results in Utah. Revenue fell

Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N) has lifted full-year revenue by around 15% to roughly £121 million, with adjusted EBITDA coming in around 10% ahead of expectations. In a trading update, the company said its £100 million acquisition of PAM Healthcare is already delivering, with £1.3 million of annualised cost synergies achieved by June. IP Group PLC (LSE:IPO) says portfolio company Istesso has begun dosing patients in a phase II trial of leramistat for muscle loss caused by rheumatoid arthritis. CEO Greg Smith calls it an important inflexion point, with the drug showing the pote

Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) says its Ghummud facility in Abu Dhabi generated $110,000 in revenue in its first full month, with 97% uptime. The company is now targeting expansion into Bahrain and Saudi Arabia using the same infrastructure-led model. Quantum Blockchain Technologies PLC (AIM:QBT) says integration of a new ASIC mining rig is complete and data is now flowing into its Method C AI Oracle. Management expects it has enough data for training, with live deployment still targeted by the end of June. Metir PLC (AIM:MET) has secured its first PFAS detector sale to Nasdaq-

Poolbeg Pharma PLC (AIM:POLB) principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss the first site activation for Poolbeg's POLB 001 TOPICAL clinical trial, evaluating the drug as a preventative treatment for cytokine release syndrome (CRS), a serious side effect linked to CAR-T and bispecific antibody therapies. The UK study will enrol 30 multiple myeloma patients receiving teclistamab, with early readouts expected due to CRS typically occurring within the first two weeks of treatment. Tremble also highlighted new data presented at the EHA Congress showing POLB 001 re

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company...

Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) for lead asset POLB 001. Cavendish reiterated its 'buy'...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a pre-investigational new drug (IND) meeting for its lead asset POLB 001. POLB 001 is being developed as a...

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, will present new data on its lead candidate POLB 001 at the European Haematology Association (EHA) congress in Stockholm next month. The poster presentation, scheduled for 13 June, outlines...

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) is in advanced talks with one of the largest private US healthcare providers to deploy its Parsortix cancer diagnostic platform. In a first quarter trading update, the company guided for revenues of at least £2.1 million this year, a 50% increase, with further upgrades possible if pipeline deals convert. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has secured a Canadian patent for its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome. CEO Jeremy Skillington says the grant strengthens the drug's appeal to pa

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received a Canadian patent approval covering the use of its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome (CRS), a potentially life-threatening...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by strong AGAMREE sales across Europe.  The company expects to hit cash flow breakeven in Q3 2026 without raising additional capital. AOTI Inc (AIM:AOTI) has published a major study showing its wound oxygen therapy healed 64.8% of patients with chronic wounds that had resisted treatment for an average of seven months.  The study, which involved 3,126-patients, also reported hospitalisation rates of just 3.7% and amputation rates of 6.1%. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF,

Oil prices have surged as the Federal Reserve begins its two-day policy meeting

EnergyPathways PLC (AIM:EPP) has launched Front End Engineering and Design for what could become the world's largest compressed air energy storage project. Pre-FEED work with Siemens Energy confirmed the project's viability, with a £15 million financing package now in place to fund the next phase. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has secured FDA Fast Track Designation for its lead cancer drug iSCIB1+ in advanced melanoma. Phase II trial data shows 77% progression-free survival at 20 months, compared with 43% for the current standard of care. Poolbeg Pharma PLC (AIM:POLB, OT